Insider Buying: AEON Biopharma, Inc. (NASDAQ:AEON) Director Purchases 60,000 Shares of Stock

AEON Biopharma, Inc. (NASDAQ:AEON) Director Jost Fischer acquired 60,000 shares of the stock in a transaction dated Tuesday, May 20th. The stock was acquired at an average cost of $0.51 per share, with a total value of $30,600.00. Following the purchase, the director now owns 206,785 shares of the company’s stock, valued at approximately $105,460.35. This trade represents a 40.88% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jost Fischer also recently made the following trade(s):

• On Monday, May 19th, Jost Fischer purchased 50,000 shares of AEON Biopharma stock. The stock was acquired at an average price of $0.50 per share, with a total value of $25,000.00.

AEON Biopharma Stock Down 2.7%

NASDAQ:AEON opened at $0.53 on Friday. The company has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $16.17. The company has a market cap of $5.62 million, a price-to-earnings ratio of 2.97 and a beta of 0.38. AEON Biopharma, Inc. has a 52 week low of $0.38 and a 52 week high of $269.28.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Dauntless Investment Group LLC purchased a new position in shares of AEON Biopharma, Inc. (NASDAQ:AEON) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,025,000 shares of the company’s stock, valued at approximately $594,000. AEON Biopharma accounts for 0.7% of Dauntless Investment Group LLC’s investment portfolio, making the stock its 18th biggest position. Dauntless Investment Group LLC owned approximately 9.73% of AEON Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.